Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 27:14:1081391.
doi: 10.3389/fgene.2023.1081391. eCollection 2023.

Clinical and genetic features of luscan-lumish syndrome associated with a novel de novo variant of SETD2 gene: Case report and literature review

Affiliations

Clinical and genetic features of luscan-lumish syndrome associated with a novel de novo variant of SETD2 gene: Case report and literature review

Yanqing Zhang et al. Front Genet. .

Abstract

Introduction: Luscan-Lumish syndrome (LLS) is currently recognized as a rarely-observed condition featured with overgrowth, macrocephaly, obesity, type I Chiari malformation, and linguistic retardation. So far, there have been only a few LLS cases registered worldwide, but with none of them reported from China. To acquire a deeper understanding on the clinical and genetic features of this disease, a Chinese boy with LLS caused by a heterozygous variant in SETD2 gene was investigated in the present study. Methods: The patient was clinically examined and the medical history of his family was collected. Genetic testing was performed to determine the genetic etiology. Results: The proband was a boy aged 5-year-7-month-old, who was referred to our hospital due to "being a slow learner in kindergarten". The child had a history of delayed motor and language development in comparison to his peers. After admission, physical examination revealed tall stature and macrocephaly as the major manifestation, in addition to a relatively lower rating in intelligence assessment as well as abnormal MRI images showing a slightly shorter corpus callosum accompanied by a mildly thinner corpus callosum body. Whole exome sequencing (WES) revealed a heterozygous c.2514_2516delTAG (p.Ser838del) variant in SETD2 gene, which was subsequently identified as a novel de novo variant. According to the standardized genetic variant classification published by the American College of Medical Genetics and Genomics (ACMG), the variant, with a pathogenicity analysis result indicating PS2 + PM2_Supporting + PM4, was determined to be likely pathogenic. Through literature review, the clinical phenotypes of the 15 LLS cases were summarized, including 8 cases of overgrowth (53%), 13 cases of macrocephaly (87%), 11 cases of developmental delay (73%), 8 cases of autism (53%), and 7 cases of special facial features (47%). Besides, abnormal craniocerebral MRI findings were noticed in 7 cases. Despite that the mutation sites of the 15 patients varied from case to case, they showed a uniformly distributed pattern throughout the whole SETD2 gene, including 5 missense mutations, 5 frameshift mutations and 5 non-sense mutations. Conclusion: LLS, not having been recognized till recent years, is identified as an autosomal dominant syndrome triggered by SETD2 gene mutation. As the first report of LLS in China, the case in our study was proved to be associated with a unique type of SETD2 gene mutation that has never been reported previously, which is believed to enrich the mutation spectrum of SETD2 gene and also, deepening the clinicians' understanding on the disease.

Keywords: SETD2; developmental delay; gene mutation; luscan-lumish syndrome; macrocephaly; tall stature.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The proband carried the c.2514_2516delTAG (p.Ser838del) mutation in SETD2 gene. (A), The results of Sanger sequencing on (C)2514_2516delTAG (p.Ser838del) mutation in SETD2 gene in the proband and his family. (B), Conservative analysis at site p. Ser838 in multiple species. (C), Distribution of the variant sites in 16 LLS patients.

Similar articles

Cited by

References

    1. Brioude F., Toutain A., Giabicani E., Cottereau E., Cormier-Daire V., Netchine I. (2019). Overgrowth syndromes - clinical and molecular aspects and tumour risk. Nat. Rev. Endocrinol. 15, 299–311. 10.1038/s41574-019-0180-z - DOI - PubMed
    1. D'Avella C., Abbosh P., Pal S. K., Geynisman D. M. (2020). Mutations in renal cell carcinoma. Urol. Oncol. 38, 763–773. 10.1016/j.urolonc.2018.10.027 - DOI - PubMed
    1. Hacker K. E., Fahey C. C., Shinsky S. A., Chiang Y. J., DiFiore J. V., Jha D. K., et al. (2016). Structure/function analysis of recurrent mutations in SETD2 protein reveals a critical and conserved role for a SET domain residue in maintaining protein stability and histone H3 lys-36 trimethylation. J. Biol. Chem. 291, 21283–21295. 10.1074/jbc.M116.739375 - DOI - PMC - PubMed
    1. Huang K. K., McPherson J. R., Tay S. T., Das K., Tan I. B., Ng C. C., et al. (2016). SETD2 histone modifier loss in aggressive GI stromal tumours. Gut 65, 1960–1972. 10.1136/gutjnl-2015-309482 - DOI - PubMed
    1. Koenning M., Wang X., Karki M., Jangid R. K., Kearns S., Tripathi D. N., et al. (2021). Neuronal SETD2 activity links microtubule methylation to an anxiety-like phenotype in mice. Brain 144, 2527–2540. 10.1093/brain/awab200 - DOI - PMC - PubMed